Three-year follow-up of advanced melanoma patients who received ipilimumab plus fotemustine in the Italian Network for Tumor Biotherapy (NIBIT)-M1 phase II study.
about
Immune Checkpoint Inhibitors: A New Opportunity in the Treatment of Ovarian Cancer?Systemic Immunotherapy for the Treatment of Brain MetastasesControl of immune cell entry through the tumour vasculature: a missing link in optimising melanoma immunotherapy?The role of the cancer stem cell marker CD271 in DNA damage response and drug resistance of melanoma cells.[Melanoma brain metastases : Treatment options].History and current state of immunotherapy in glioma and brain metastasis.Baseline neutrophil-to-lymphocyte ratio is associated with outcome of ipilimumab-treated metastatic melanoma patients.Immunological markers and clinical outcome of advanced melanoma patients receiving ipilimumab plus fotemustine in the NIBIT-M1 study.Are immune checkpoint blockade monoclonal antibodies active against CNS metastases from NSCLC?-current evidence and future perspectives.Immunotherapy biomarkers 2016: overcoming the barriers.Single versus combination immunotherapy drug treatment in melanoma.Harnessing the immune system for the treatment of melanoma: current status and future prospects.Melanoma central nervous system metastases: current approaches, challenges, and opportunities.Targeting immune checkpoints in unresectable metastatic cutaneous melanoma: a systematic review and meta-analysis of anti-CTLA-4 and anti-PD-1 agents trialsEarly analysis of surrogate endpoints for metastatic melanoma in immune checkpoint inhibitor trials.Ipilimumab in melanoma.Immunological effects of chemotherapy and radiotherapy against brain tumors.Immune Checkpoint Inhibitors for Brain Metastases.Challenges in the delivery of therapies to melanoma brain metastases.Baseline neutrophils and derived neutrophil-to-lymphocyte ratio: prognostic relevance in metastatic melanoma patients receiving ipilimumab.Tumor-Localized Secretion of Soluble PD1 Enhances Oncolytic Virotherapy.High neutrophil to lymphocyte ratio measured before starting ipilimumab treatment is associated with reduced overall survival in patients with melanoma.Prognostic significance of hematological profiles in melanoma patients.Management of intracranial melanomas in the era of precision medicine.Cancer Immunotherapy Getting Brainy: Visualizing the Distinctive CNS Metastatic Niche to Illuminate Therapeutic Resistance.Trial watch: Immune checkpoint blockers for cancer therapy.Cure in Advanced Renal Cell Cancer: Is It an Achievable Goal?Current chemotherapeutic regimens for brain metastases treatment.Defining the Most Appropriate Primary End Point in Phase 2 Trials of Immune Checkpoint Inhibitors for Advanced Solid Cancers: A Systematic Review and Meta-analysis.Current status and perspectives in immunotherapy for metastatic melanoma.Mechanisms and Therapy for Cancer Metastasis to the Brain.Immune Checkpoint Inhibitors for the Treatment of Central Nervous System (CNS) Metastatic DiseasePretreatment hematological markers predict clinical outcome in cancer patients receiving immune checkpoint inhibitors: A meta-analysis
P2860
Q26742047-936F026B-D4EE-46DB-BB92-CD8811A6E89CQ26750891-AAF73370-70E8-4760-B424-32B8353BAEC6Q29994573-3907075A-A636-40C8-ADCE-EA7BE1A6E0FDQ30837718-EFE68D24-7DBC-4587-90D2-5D6C2FCD457EQ31098294-346A3C7C-E41E-49B6-BEA3-8A00021AC49DQ33656811-07F25793-40AA-47A9-85BF-48658A3C8247Q36086834-A45F31C5-010D-4C3C-85D5-D7688F19F8C4Q36711007-EEC93AB7-CD4D-47A5-9BDF-D4DCC72D33CCQ37584395-681E0984-05FE-4A90-8E62-2D3392144B19Q37713438-C789C090-6923-4158-98E6-81D88786DC35Q38661099-E47B62B8-FFCD-48FA-9647-6B245A0D8C7FQ38806243-231588C6-C008-465D-9870-A3E9592397BEQ38807942-D7904CAA-BFA6-416F-A81E-6DC7D30BF809Q38831830-130DC3EC-0BD8-438A-89A8-45CF3EAB650FQ38846255-9534C957-0285-486E-B864-7EA001B2E438Q38893697-323A3419-1ADF-4113-B564-54B5E0D5B9A9Q38947116-E4CC98B7-5B1D-4F84-A751-1B7035C5FD4BQ39247421-2E9A6424-0F67-4BE2-9149-715E85A26E3FQ39331752-AAFF8CCC-5FE4-48DF-9EEC-967962A43C94Q40070782-DC21BFB9-3AB8-4ED6-A203-C8C08645566CQ40287020-BF11EB61-BE6F-4F51-9C25-C5344665A0FDQ40569572-003AB819-3782-4F09-B8CA-647CA15897E2Q40723817-C0DFAC0C-34D7-4C9C-B336-67FC5488AC10Q44959749-4FBB80CC-EEED-4E56-996C-F05C9AB1180DQ46900302-B2D2A9AF-8F78-441E-A201-01CFD392CE68Q47393365-CB053263-4D48-4058-A71F-29F3E0BA54DEQ47835640-18E49705-23AB-42C7-BB9B-CA167976CBC3Q48109517-8030FE59-6BE9-4525-9649-F060D6379216Q52690105-C25D77F2-3A6E-473E-864A-DC3D544ACF02Q54574397-8D6E8B6B-6674-418A-AC84-009D020FBDA4Q54950354-DEED4606-FD1F-4A42-9D75-A0D692A84857Q57490955-0BD4B132-FC98-477C-B18A-7CF6609CEBF2Q58700048-4345F3C3-5D96-4E32-8BD6-0DF99949436E
P2860
Three-year follow-up of advanced melanoma patients who received ipilimumab plus fotemustine in the Italian Network for Tumor Biotherapy (NIBIT)-M1 phase II study.
description
2014 nî lūn-bûn
@nan
2014年の論文
@ja
2014年学术文章
@wuu
2014年学术文章
@zh
2014年学术文章
@zh-cn
2014年学术文章
@zh-hans
2014年学术文章
@zh-my
2014年学术文章
@zh-sg
2014年學術文章
@yue
2014年學術文章
@zh-hant
name
Three-year follow-up of advanc ...... apy (NIBIT)-M1 phase II study.
@en
Three-year follow-up of advanc ...... n Network for Tumor Biotherapy
@nl
type
label
Three-year follow-up of advanc ...... apy (NIBIT)-M1 phase II study.
@en
Three-year follow-up of advanc ...... n Network for Tumor Biotherapy
@nl
prefLabel
Three-year follow-up of advanc ...... apy (NIBIT)-M1 phase II study.
@en
Three-year follow-up of advanc ...... n Network for Tumor Biotherapy
@nl
P2093
P50
P356
P1433
P1476
Three-year follow-up of advanc ...... apy (NIBIT)-M1 phase II study.
@en
P2093
A M Di Giacomo
C Maccalli
E Fonsatti
G Parmiani
P A Ascierto
P304
P356
10.1093/ANNONC/MDU577
P50
P577
2014-12-23T00:00:00Z